Trial Profile
Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Ifosfamide (Primary) ; Antineoplastics; Dexamethasone; Doxorubicin; Mesna; Vincristine
- Indications Chemotherapy-induced nausea and vomiting; Sarcoma
- Focus Pharmacokinetics; Therapeutic Use
- 11 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Primary endpoint has been met (Area under the drug concentration-time curve Ifosfamide AUC), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Primary endpoint has been met (Complete Response), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.